Every cell in the human body runs a protein-folding factory inside a compartment called the endoplasmic reticulum, or ER. When that factory jams, misfolded proteins pile up like crumpled parts on an assembly line, a process tied to aging and neurodegenerative diseases including Alzheimer’s. A study published in April 2026 in Nature Cell Biology now identifies a specific molecular gatekeeper that keeps the factory running: a transporter protein called SLC33A1, which clears a spent form of the antioxidant glutathione out of the ER before it can gum up the works.
The finding gives researchers a concrete target in a field that has long understood the broad importance of glutathione but lacked a clear picture of how cells move it across the ER membrane.
Why the ER needs an oxidizing environment
The ER is not like the rest of the cell. Its interior is deliberately kept in a more oxidized chemical state, a condition that has been recognized since early biochemical work in the 1990s. That oxidizing environment is essential because it allows disulfide bonds to form, the chemical cross-links that lock newly made proteins into their correct three-dimensional shapes. Without those bonds, proteins emerge floppy and prone to clumping.
The machinery that drives this process is well understood. An enzyme relay involving Ero1 and protein disulfide isomerase (PDI) passes electrons through a chain that ultimately stitches disulfide bonds into nascent proteins. This Ero1-PDI pathway, detailed in Science, acts as the biochemical engine of oxidative folding. When it works, proteins leave the ER correctly shaped. When it stalls or is overwhelmed, misfolded proteins accumulate and trigger stress responses.
Glutathione sits at the center of this balancing act. Inside the ER, it exists mostly in its oxidized form, abbreviated GSSG. That ratio matters: too much reduced glutathione would undermine disulfide-bond formation, while too much oxidized glutathione signals that the system is overloaded. And glutathione’s role does not stop at folding. A 2019 study in Nature Communications showed that when glutathione balance collapses, cells also lose the ability to run autophagy, the cleanup process that digests and recycles damaged or aggregated proteins. In short, glutathione supports both the assembly line and the quality-control department.
What the new study found
The Nature Cell Biology study focused on a protein already known to biologists but in a different context. SLC33A1, sometimes called AT-1, was previously characterized as a transporter of acetyl-CoA into the ER, where that molecule is used to modify proteins. Mutations in SLC33A1 cause Huppke-Brendel syndrome, a rare neurological disorder, and variants in the gene have been linked to susceptibility to autism spectrum disorder.
The new research adds a second job description. Using cultured human cells, the team found that SLC33A1 also exports GSSG out of the ER. When the researchers knocked out SLC33A1, oxidized glutathione accumulated inside the compartment, the redox balance shifted, disulfide-bond formation faltered, and misfolded proteins began to aggregate. Restoring SLC33A1 reversed the buildup.
The proposed mechanism is straightforward: as the Ero1-PDI relay generates disulfide bonds, it produces GSSG as a byproduct. SLC33A1 acts like a drain, moving that spent glutathione out of the ER so the compartment does not become too oxidized for efficient folding. Block the drain, and the factory floods.
Competing and complementary explanations
SLC33A1 is not the only candidate for glutathione traffic across the ER membrane. A 2017 study in Molecular Cell reported that Sec61, a protein channel better known for threading newly made proteins into the ER, also mediates glutathione import into the compartment, regulated by the ER folding factors Ero1 and BiP.
The two findings are not necessarily in conflict. Sec61 may handle inbound traffic of reduced glutathione while SLC33A1 manages outbound export of the oxidized form. Together, they could form a two-way valve that keeps the ER’s redox environment in a narrow, productive range. But no published experiment has yet tested both transport routes side by side in the same system, so the relationship between them remains an open question.
There is also the matter of how tightly SLC33A1 activity is coupled to the folding relay itself. If the transporter sits downstream of Ero1 and PDI, then changes in folding demand, during a viral infection, for example, or in cells that secrete large quantities of protein, could indirectly alter how hard SLC33A1 has to work. The Nature Cell Biology paper suggests such coupling exists but does not yet quantify it.
What the study does not show
Several important gaps remain. The experiments were conducted in cultured cells, not in living animals. Overexpression and knockout approaches can reveal whether a protein is necessary for a given function, but they do not always reflect how that protein behaves at its natural levels in tissues with heavy secretory loads, such as pancreatic beta cells or neurons. Without measurements of ER glutathione dynamics in those tissues, extrapolating to whole organisms is premature.
No animal model has yet demonstrated that manipulating SLC33A1 reduces the burden of misfolded proteins or slows progression in diseases marked by ER stress. And while SLC33A1 mutations are already associated with neurological conditions, no clinical data directly connect natural variation in the gene to risk for common protein-aggregation diseases like Alzheimer’s or Parkinson’s.
Readers may also wonder whether taking glutathione supplements could help. The answer, based on current evidence, is that oral glutathione has poor bioavailability and does not reliably alter ER redox conditions. The problem the study highlights is not a shortage of glutathione in the body but a failure to move its oxidized form out of a specific cellular compartment. That distinction matters for anyone evaluating supplement marketing claims.
Where the research goes from here
What makes the SLC33A1 finding notable is its specificity. Rather than a vague link between antioxidants and cell health, it identifies a single protein with a defined biochemical job. That precision opens the door to concrete experiments: Does boosting SLC33A1 reduce protein aggregation under stress? Does its activity decline with age or in cells expressing aggregation-prone proteins tied to neurodegeneration? How does it coordinate with Sec61?
For now, the most accurate reading is that SLC33A1 adds a significant piece to a puzzle still being assembled. Decades of established work explain why glutathione must be tightly controlled inside the ER. The new transporter data offer one plausible route by which cells achieve that control. Studies comparing SLC33A1 and Sec61 in the same system, tracking ER glutathione in living tissues, and probing links to disease models will determine whether this gatekeeper is one player among many or a central switch in the survival decisions of stressed cells.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
